<DOC>
	<DOCNO>NCT00618267</DOCNO>
	<brief_summary>The purpose study see find new way test certain Multiple Sclerosis ( MS ) medication work body well understand medicine change certain substance ( cell ) find immune ( protective ) system . Blood test drawn follow : - Use new method call `` Immuknow® '' Test see method help good understand MS medicine work . - Measure certain level immune cell new way , see help understand body 's response MS medicine . These method test MS take MS medication , help u compare result . About 100 subject enrol study Partners Multiple Sclerosis Center Brigham Women 's Hospital . Biogen Idec , Inc. Cambridge , MA , pay study do .</brief_summary>
	<brief_title>ATP Expression Lymphocytes MS Patients Means `` ImmuKnow® '' Assay .</brief_title>
	<detailed_description>The primary objective study determine effect various therapy ( immunomodulatory well immunosuppressive ) ATP level CD4+ cell determine whether `` ImmuKnow® '' assay appropriate screening tool ass immunocompetence potential Tysabri patient . Secondary objective correlate expression ATP CD4+ cell CD4+ cell count . Tertiary objective examine level regulatory T-cells ( CD4+ CD25+ ) MS patient possible correlation therapy use , well recently propose marker regulatory T-cells , LAP , correlate CD25 marker .</detailed_description>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>1 . Patients must take 1 follow medication 3 month : Cytoxan , Cellcept , Novantrone Betaseron , Rebif , Avonex Copaxone . 2 . Patients must able provide write informed consent . 1 . Patients combination multiple medication . 2 . Restricted treatment whereby use 50 day prior enrollment visit permit : systemic steroid . 3 . With educational completion 8th grade school equivalent nonfluent English . 4 . Any reason , opinion Investigator and/or Sponsor , patient determine suitable study participation .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>